Patent assignee · FR · COMPANY

OSE IMMUNOTHERAPEUTICS

🏢 View company profile →
27Patents
27Active
27Granted
53Portfolio score

Filing activity: Jan 13, 2010 → Sep 9, 2022

Most-cited patents

PatentTitleAreaCited byStatus
US9447182B2 Antibodies directed against the alpha chain of IL7 receptor—their use for the preparation of drug candidates Chemistry; Metallurgy 4 Active
US10434157B2 Therapeutic multi-peptides T specific immune therapy for treatment of brain metastasis Human Necessities 3 Active
US10364287B2 Anti-CD28 humanized antibodies Chemistry; Metallurgy 3 Active
US11325959B2 Method for manufacturing a stable emulsion for peptide delivery Human Necessities 2 Active
US10428152B2 Antibodies directed against CD127 Physics 2 Active
US11191820B2 Method for inducing early T memory response with short peptides anti-tumor vaccine Human Necessities 2 Active
US11352430B2 Humanized anti-human-PD-1 antibody and its use in cancer treatment Chemistry; Metallurgy 2 Active
US9562098B2 Anti-CD28 humanized antibodies Chemistry; Metallurgy 2 Active
US11279766B2 Anti-SIRPa antibodies and their therapeutic applications Physics 2 Active
US9587023B2 Recombinant monovalent antibodies Emerging Cross-Sectional Technologies 1 Active
US11440964B2 Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody Physics 1 Active
US11098128B2 Antibodies and polypeptides directed against CD127 Chemistry; Metallurgy 0 Active
US11365257B2 Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1) Chemistry; Metallurgy 0 Active
US12371502B2 Antibodies directed against CD127 Physics 0 Active
US11230602B2 Non-antagonistic antibodies directed against the alpha chain of the IL7 receptor extracellular domain and use thereof in cancer treatment Chemistry; Metallurgy 0 Active
US12091464B2 Method of promoting a t-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1) Chemistry; Metallurgy 0 Active
US12331118B2 Humanized anti-human-PD-1 antibody and methods of using them for cancer treatment Chemistry; Metallurgy 0 Active
US11926671B2 Antibodies and polypeptides directed against CD127 Chemistry; Metallurgy 0 Active
US12331115B2 Uses of anti-SIRPg antibodies Physics 0 Active
US11981713B2 Method for manufacturing a stable emulsion for peptide delivery Human Necessities 0 Active
US10689444B2 Recombinant monovalent antibodies Emerging Cross-Sectional Technologies 0 Active
US12252546B2 Anti-SIRPa antibodies and their therapeutic applications Physics 0 Active
US11884723B2 Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies Emerging Cross-Sectional Technologies 0 Active
US12258577B2 Method effector cells using anti-CD127 antibodies for applications in cell therapy Chemistry; Metallurgy 0 Active
US11713356B2 Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.